Daiichi Sankyo: all 498 studies

Page 1 of 5. Open to participants first (39), then studies with results posted, then the rest; newest registration first within each.

• A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]RecruitingNCT07890714Phase 1/2
• TROPION Breast Respond in 1L TNBCNot yet recruitingNCT07867470
• Medical Access Program for Valemetostat Tosylate (DS 3201b) For The Treatment of Patients With Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL)AvailableNCT07862465
• A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)Not yet recruitingNCT07791732Phase 3
• A Study of DS-3939a in Participants With Solid TumorsNot yet recruitingNCT07739966Phase 1/2
• A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast CancerRecruitingNCT07701941Phase 1/2
• T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdRecruitingNCT07683754Phase 3
• First-in-Human Trial of DS1025a in Participants With Advanced Solid TumorsRecruitingNCT07681882Phase 1
• A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular EventsNot yet recruitingNCT07474649Phase 3
• A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)RecruitingNCT07244341Phase 1
• A First-in-Human Trial of DS3790a in Participants With Hematological MalignanciesRecruitingNCT07220616Phase 1/2
• A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed DyslipidaemiaRecruitingNCT07206472
• A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate CancerRecruitingNCT07189403Phase 1
• A Study of DS5361b in Participants With Advanced Solid TumorsRecruitingNCT07182591Phase 1
• A Study of DS3610a in Participants With Advanced Solid TumorRecruitingNCT07159126Phase 1
• Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial CarcinomaRecruitingNCT07129993Phase 2/3
• Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial CancerRecruitingNCT07022483Phase 3
• A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid TumorsRecruitingNCT07015697Phase 1
• Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerRecruitingNCT06899126Phase 3
• Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996
• Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete RemissionRecruitingNCT06824168Phase 2
• Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)RecruitingNCT06819007Phase 3
• Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)RecruitingNCT06809764
• Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic ImpairmentRecruitingNCT06740799Phase 1
• Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Phase 3
• A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Phase 3
• First-in-Human Trial of DS-2243a in Participants With Advanced Solid TumorsRecruitingNCT06644755Phase 1
• A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)RecruitingNCT06362252Phase 1/2
• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)RecruitingNCT06330064Phase 1/2
• A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)RecruitingNCT06210776
• A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerRecruitingNCT06203210Phase 3
• A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)RecruitingNCT06174987Phase 3
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06172478Phase 2
• A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube CancerRecruitingNCT06161025Phase 2/3
• Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast CancerRecruitingNCT05950945Phase 3
• DESTINY Breast Respond HER2-(Ultra)Low EuropeRecruitingNCT05945732
• First-in-Human Study of DS-3939a in Participants With Advanced Solid TumorsRecruitingNCT05875168Phase 1/2
• A Study of DS-1103a Combination Therapy in Participants With Advanced Solid TumorsRecruitingNCT05765851Phase 1
• A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) TreatmentRecruitingNCT04635111
• A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton SyndromeTerminatedNCT05979831Phase 1/2Results posted
• A Study of DS-7011a in Patients With Systemic Lupus ErythematosusCompletedNCT05638802Phase 1/2Results posted
• A Study of DS-1211b in Individuals With PseudoXanthoma ElasticumCompletedNCT05569252Phase 2Results posted
• A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy SubjectsCompletedNCT04796831Phase 1Results posted
• Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal CancerCompletedNCT04744831Phase 2Results posted
• A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in JapanCompletedNCT04703322Phase 2Results posted
• Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)Active, not recruitingNCT04703192Phase 2Results posted
• Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)Active, not recruitingNCT04656652Phase 3Results posted
• Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)CompletedNCT04644237Phase 2Results posted
• HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung CancerActive, not recruitingNCT04619004Phase 2Results posted
• Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With PexidartinibCompletedNCT04526704Phase 4Results posted
• A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCTActive, not recruitingNCT04488822Phase 3Results posted
• Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)CompletedNCT04484142Phase 2Results posted
• A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal CancerTerminatedNCT04479436Phase 2Results posted
• A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic ImpairmentCompletedNCT04473664Phase 1Results posted
• A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy ParticipantsCompletedNCT04459598Phase 1Results posted
• A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy ParticipantsCompletedNCT04459585Early Phase 1Results posted
• DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)TerminatedNCT04276415Phase 1Results posted
• Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR EventsCompletedNCT04271280Results posted
• Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044CompletedNCT04269707Phase 3Results posted
• Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy ParticipantsCompletedNCT04223635Early Phase 1Results posted
• DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)CompletedNCT04014075Phase 2Results posted
• Study of Mirogabalin for Central Neuropathic PainCompletedNCT03901352Phase 3Results posted
• Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy VolunteersCompletedNCT03901313Phase 1Results posted
• Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]CompletedNCT03734029Phase 3Results posted
• Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)CompletedNCT03672097Phase 4Results posted
• Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)CompletedNCT03671564Phase 1Results posted
• DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung CancerTerminatedNCT03599518Phase 1Results posted
• Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)TerminatedNCT03552029Phase 1Results posted
• DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]CompletedNCT03529110Phase 3Results posted
• DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]CompletedNCT03523585Phase 3Results posted
• Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial CancerCompletedNCT03523572Phase 1Results posted
• Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDACompletedNCT03523117Phase 3Results posted
• DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung CancerTerminatedNCT03505710Phase 2Results posted
• Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac DiseaseCompletedNCT03395639Phase 3Results posted
• DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)CompletedNCT03384940Phase 2Results posted
• Study of DS-8201a for Participants With Advanced Solid Malignant TumorsCompletedNCT03383692Phase 1Results posted
• DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) ProteinCompletedNCT03368196Phase 1Results posted
• Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast CancerCompletedNCT03366428Phase 1Results posted
• DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]CompletedNCT03329690Phase 2Results posted
• Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)CompletedNCT03291288Phase 1Results posted
• DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung CancerTerminatedNCT03255083Phase 1Results posted
• A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)TerminatedNCT03248492Phase 2Results posted
• Safety of DS-1040b in Acute Ischemic Stroke Patients Treated With ThrombectomyCompletedNCT03198715Not applicableResults posted
• DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)TerminatedNCT03110354Phase 1Results posted
• Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-StudyCompletedNCT03037931Phase 3Results posted
• Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) MutationCompletedNCT02984995Phase 2Results posted
• Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast CancerCompletedNCT02980341Phase 1/2Results posted
• A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated MelanomaCompletedNCT02975700Not applicableResults posted
• Tenosynovial Giant Cell Tumors (TGCT) Observational Platform ProjectCompletedNCT02948088Results posted
• Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in EuropeCompletedNCT02943993Results posted
• Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)CompletedNCT02943785Phase 3Results posted
• Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter AblationCompletedNCT02942576Phase 3Results posted
• Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary EmbolismCompletedNCT02923115Phase 1/2Results posted
• Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary InterventionCompletedNCT02866175Phase 3Results posted
• Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT02834390Phase 1Results posted
• Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency AnemiaTerminatedNCT02826681Phase 2Results posted
• Study of DU-176b Aged 80 Years or OlderCompletedNCT02801669Phase 3Results posted
• Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)CompletedNCT02798471Phase 3Results posted
• Study of Pexidartinib in Asian Subjects With Advanced Solid TumorsCompletedNCT02734433Phase 1Results posted
• Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)CompletedNCT02668653Phase 3Results posted

← Daiichi Sankyo overview and focus areas